Clinical Trial Update: Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX) for Refractory/Relapsed B-cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial results for R-GEMOX (rituximab, gemcitabine, oxaliplatin) in refractory/relapsed B-cell lymphoma, including diffuse large B-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• OXALIPLATIN (Oxaliplatin)
• Rituximab (rituximab)

Snippet

Sponsor: Lymphoma Study Association | Conditions: Diffuse Large Cell Lymphoma | Phase 2 | Status: COMPLETED